Dear Colleague,On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium ‘Navigating New Waters in mRCC’. The symposium will be held on Friday, 19th October from 18:00 to 19:30 during the ESMO 2018 Congress.

With the introduction of targeted therapies and immunotherapies, the mRCC treatment landscape has changed dramatically in recent years. In this new world of therapy options, it is important to share knowledge and experience so that we may better navigate these uncharted waters and further improve mRCC patient outcomes.

During this symposium, I will be joined by an expert faculty and together we hope to guide you through this complex sea of treatment options. We will look to the horizon, and explore the latest data and future treatment possibilities. There will also be an opportunity for you to interact with the panel and take part in the discussions.

My colleagues and I look forward to welcoming you in Munich for what promises to be a valuable and informative symposium.

Bernard Escudier, ChairGustave Roussy Villejuif, France

Chair’s invitation

This meeting is organised and funded by Pfizer.© 2018 Pfizer Pharma GmbH. All rights reserved.July 2018. PP-ONC-DEU-0448www.pfizer.com

Friday 19 October 2018, 18:00–19:30 Hall B3 – Room 21, Messe Munich, Munich, Germany

ESMO 2018 Industry Satellite Symposium

Navigating New Waters in mRCC

ProgrammeChair: Bernard Escudier

18:00–18:10 Mapping the Journey: Welcome and Introduction Bernard Escudier (France)

18:10–18:30 Navigating Towards Improved Outcomes in mRCC: What are the Prognostic Characteristics to Consider? Avishay Sella (Israel)

18:30–18:50 Tales from the Sea: How to Choose mRCC Treatments in the Evolving Treatment Landscape? Bernard Escudier (France)

18:50–19:10 What’s on the Radar in mRCC? Manuela Schmidinger (Austria)

19:10–19:20 Consulting the Compass: Q&A All faculty, facilitated by Bernard Escudier (France)

19:20–19:30 Dropping Anchor: Summary and Close Bernard Escudier (France)